Secukinumab, a novel anti-IL-17A antibody, can be quantified in skin after a single dose by dermal open flow microperfusion (dOFM)

Publication from Health

Bruin G., Dragatin C. , Aigner B., Polus F., Calonder C., Froeliger C., Tiffner K., Bodenlenz M., Mader J., Korsatko S., Ratzer R., Pieber T. R., Loesche C., Sinner F.

Journal der Deutschen Dermatologischen Gesellschaft 12:15-15, 2014